Eqis Capital Management, Inc. Gilead Sciences, Inc. Transaction History

Eqis Capital Management, Inc.

$1.21 Billion
Q3 2024

A detailed history of Eqis Capital Management, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 13,724 shares of GILD stock, worth $1.29 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

13,724

Previous 15,383 10.78%

Holding current value

$1.29 Million

Previous $1.06 Million 9.0%

% of portfolio

0.09%

Previous 0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$66.59 - $83.99 $110,472 - $139,339	-1,659 Reduced 10.78%	13,724 $1.15 Million
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $24,817 - $28,641	393 Added 2.62%	15,383 $1.06 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $127,412 - $155,376	-1,780 Reduced 10.61%	14,990 $1.1 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $4,616 - $5,234	-63 Reduced 0.37%	16,770 $1.36 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $142,630 - $155,612	-1,929 Reduced 10.28%	16,833 $1.26 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $77,454 - $88,347	-1,019 Reduced 5.15%	18,762 $1.45 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $332,201 - $378,479	-4,297 Reduced 17.85%	19,781 $1.64 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $99,649 - $143,062	1,599 Added 7.11%	24,078 $2.07 Million
Q3 2022 Oct 24, 2022	BUY	$59.54 - $68.01 $32,985 - $37,677	554 Added 2.53%	22,479 $1.39 Million
Q2 2022 Aug 08, 2022	SELL	$57.72 - $65.01 $271,918 - $306,262	-4,711 Reduced 17.69%	21,925 $1.36 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $2.18 Million - $2.73 Million	-37,638 Reduced 58.56%	26,636 $1.58 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $169,661 - $192,568	-2,615 Reduced 3.91%	64,274 $4.67 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $87,320 - $94,208	-1,290 Reduced 1.89%	66,889 $4.67 Million
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $599,220 - $654,733	-9,441 Reduced 12.16%	68,179 $4.7 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $184,860 - $210,925	-3,081 Reduced 3.82%	77,620 $5.02 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $185,358 - $211,207	3,272 Added 4.23%	80,701 $4.7 Million
Q3 2020 Nov 10, 2020	BUY	$62.1 - $78.08 $459,043 - $577,167	7,392 Added 10.55%	77,429 $4.89 Million
Q2 2020 Aug 10, 2020	SELL	$72.34 - $84.0 $529,745 - $615,132	-7,323 Reduced 9.47%	70,037 $5.39 Million
Q1 2020 May 12, 2020	BUY	$62.63 - $80.22 $428,076 - $548,303	6,835 Added 9.69%	77,360 $5.33 Million
Q4 2019 Jan 24, 2020	BUY	$61.62 - $67.78 $212,897 - $234,179	3,455 Added 5.15%	70,525 $4.58 Million
Q3 2019 Nov 05, 2019	BUY	$62.51 - $69.0 $58,946 - $65,067	943 Added 1.43%	67,070 $4.25 Million
Q2 2019 Jul 18, 2019	SELL	$61.87 - $69.38 $1.28 Million - $1.43 Million	-20,665 Reduced 23.81%	66,127 $4.47 Million
Q1 2019 Apr 18, 2019	SELL	$62.53 - $70.05 $154,824 - $173,443	-2,476 Reduced 2.77%	86,792 $5.64 Million
Q4 2018 Jan 25, 2019	SELL	$60.54 - $79.0 $424,688 - $554,185	-7,015 Reduced 7.29%	89,268 $5.58 Million
Q3 2018 Oct 17, 2018	SELL	$71.28 - $78.92 $611,012 - $676,502	-8,572 Reduced 8.18%	96,283 $7.15 Million
Q2 2018 Jul 27, 2018	BUY	$64.88 - $75.68 $2.15 Million - $2.51 Million	33,105 Added 46.14%	104,855 $7.43 Million
Q1 2018 Apr 06, 2018	BUY	$72.84 - $88.8 $528,017 - $643,711	7,249 Added 11.24%	71,750 $5.41 Million
Q4 2017 Jan 25, 2018	SELL	$71.15 - $83.52 $120,456 - $141,399	-1,693 Reduced 2.56%	64,501 $4.62 Million
Q3 2017 Oct 03, 2017	BUY	$72.11 - $85.47 $4.77 Million - $5.66 Million	66,194	66,194 $5.36 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.

Account

Eqis Capital Management, Inc. Gilead Sciences, Inc. Transaction History